Previous 10 | Next 10 |
COMPASS Pathways is a biotech psychedelic medicine development and therapy company that has developed a synthetic formulation of psilocybin, COMP360, for combatting treatment-resistant depression. Received the highly-valuable FDA Breakthrough Therapy Designation for COMP360 trials and...
FinancialBuzz.com News Commentary New York, NY (12/14/2020) – There is a plethora of innovations that scientists and researchers have accomplished in biotechnology in recent years. Among the popular fields of study for biotech companies are gene editing, tissue engineering and re...
Palm Beach, FL – December 8, 2020 – The psychedelics drugs market has seen a surge in popularity over the past decade in the U.S. Psychedelics have been familiarly involved with healing and mental treatment practices with mind-altering substances since the dawn of time...
Billionaires, like Peter Thiel are investing in psychedelic stocks. In fact, he just backed ATAI Life Sciences in a $125 million funding round. “ATAI’s great virtue is to take mental illness as seriously as we should have been taking all illness all along,” Thiel, who c...
Are Psychedelic Stocks On Your Watch List Right Now Guess what, psychedelic stocks are a thing and penny stocks are benefiting right now. While the early rumors that magic mushroom stocks would become the next “cannabis industry”, it’s never easy believi...
Psychedelics could soon revolutionize mental health. After all, “Traditional medicines that are treating things like depression, addiction, and anxiety really are seeking to numb and mask the issues that surround these illnesses. So, things like Xanax, while they might make you feel ...
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – December 1, 2020 – Thanks in large part to the global COVID-19 pandemic, 2020 has been a year of tremendous challenges and adversity. But those historic challenges have also ...
Shares of Compass Pathways (NASDAQ: CMPS) have soared since the company's recent stock market debut as support grows for the use of popular recreational drugs to combat depression. Can the highly refined version of magic mushrooms that Compass Pathways is developing for depressi...
Sunesis Pharmaceuticals (SNSS) +50% after announcing merger agreement with Viracta Therapeutics.China Automotive Systems (CAAS) +32% on guiding 2021 sales boom.India Globalization Capital (IGC) +24%.Ameri Holdings (AMRH) +26%.Oramed Pharmaceuticals (ORMP) +24%.Navios ...
Oregon and DC lead the way with decriminalization. New Jersey and California may follow in Oregon's footsteps. 2021 will be a major year for Psychedelics. For further details see: Tripping Over Future Psychedelic Catalysts
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...